ABSTRACT
The purpose is to verify whether patients with Long Covid-19 symptoms can recover Functional Capabilities and Endurance reaching the normotype subjects' level. The study is a before-after trial comparing the affected sample with baseline normotype data. The study was carried out at the private clinic "Move Different" near Aosta Italy. The clinic has an agreement with public health for a project for patients with Long Covid-19 symptoms. About 60 subjects (mean age 62+-3) healed from Covid-19 Virus with more than one day of hospitalization, older than 60 years old were included. They were divided into two clusters: Low Performance Patients (LPP) and Medium Performance Patients (MPP), decided by the Medical Equipe. The program consisted of 10 sessions of 1h, divided into 2/3 treatments per week;based on the use of Virtual Reality and Augmented Reality through a Digital Mirror. Tests were performed before and after the intervention. Increase in meters covered in the 6 Minutes Walking Test (MPP increases 56+- 65 meters, LPP increases 99+-74 meters). Wilcoxon test was performed between pre and post 6MWT for both of populations (pvalue < 0.005, pvalue < 0.005). After the treatment, results are close to normative data of Perera et al, 2006, Geriatrics. The improvement of both groups is statistically significantly difference;data support that especially the medium-functional group achieves the similar level of normotype subjects. A future randomized control trial aimed at testing whether improvement of this method over a traditional one is suggested. The authors declared no potential conflicts of interest with respect to the research authorship and/or publication of this poster.
ABSTRACT
The purpose is to verify whether patients with Long Covid-19 symptoms can recover Functional Capabilities and Endurance reaching the normotype subjects' level. The study is a before-after trial comparing the affected sample with baseline normotype data. The study was carried out at the private clinic "Move Different" near Aosta Italy. The clinic has an agreement with public health for a project for patients with Long Covid-19 symptoms. About 60 subjects (mean age 62+-3) healed from Covid-19 Virus with more than one day of hospitalization, older than 60 years old were included. They were divided into two clusters: Low Performance Patients (LPP) and Medium Performance Patients (MPP), decided by the Medical Equipe. The program consisted of 10 sessions of 1h, divided into 2/3 treatments per week;based on the use of Virtual Reality and Augmented Reality through a Digital Mirror. Tests were performed before and after the intervention. Increase in meters covered in the 6 Minutes Walking Test (MPP increases 56+- 65 meters, LPP increases 99+-74 meters). Wilcoxon test was performed between pre and post 6MWT for both of populations (pvalue < 0.005, pvalue < 0.005). After the treatment, results are close to normative data of Perera et al, 2006, Geriatrics. The improvement of both groups is statistically significantly difference;data support that especially the medium-functional group achieves the similar level of normotype subjects. A future randomized control trial aimed at testing whether improvement of this method over a traditional one is suggested. The authors declared no potential conflicts of interest with respect to the research authorship and/or publication of this poster.
ABSTRACT
BACKGROUND: Patients affected by pre-existing chronic spontaneous/Inducible urticaria (CSU/CIU) still feel unsafe due to the potential risk of an Adverse Event Following Immunization (AEFI) and Cutaneous Adverse Reactions (CARs) of COVID-19 vaccines. The appropriate management in this field remains debated and evidence is still lacking. METHODS: We considered 160 CSU/CIU patients in Omalizumab/antihistamine therapy who received two doses of Comirnaty/Moderna mRNA vaccines; 20 of them also received a booster dose. Urticaria Activity Score-7 (UAS7) was used to assess the severity of the disease. Demographics, medical history, AEFI and CARs outcome after vaccination were collected by administering a web-based questionnaire completed by phone interview. RESULTS: In total, 147 patients did not show urticaria relapse (91.88%). Worsening cutaneous symptoms were experienced by 13 of our patients (8.12%). Exacerbation had a mean duration of 2 days and 11 h and mostly occurred after the first dose (69.23%). Systemic mild side effects were experienced by 9 patients (5.62%). No severe reactions were observed. CONCLUSIONS: Omalizumab can potentially prevent CARs and AEFI; however, major problems were registered during the 2-month stop period scheduled in the treatment. We suggest patients should not undergo vaccination during this period. CSU/CIU exacerbations appear to be transient and can be managed by antihistamines.
ABSTRACT
After coronavirus disease 2019 (COVID-19) caused a global pandemic, vaccines were rapidly developed to control the spread of the virus. Although they were effective in most of the cases at protecting people from becoming seriously ill and being hospitalized, they showed side effects, too. Among other adverse vaccine reactions, cutaneous eruptions following SARS-CoV-2 have been described in the literature, but they are not well-characterized yet. We described the morphology and timing of the spectrum of cutaneous reactions following most of the COVID-19 vaccines available in Italy, which were observed in outpatients referred to our non-invasive diagnostic clinic. Most of these reactions appeared after the second or third COVID-19 vaccine dose (most of them after mRNA COVID-19 vaccines). Our data support that cutaneous reactions to COVID-19 vaccination are generally self-limited; in addition, history of allergic reaction to a specific food, medicine or vaccine should not discourage vaccination in the general population, although patients with immune dysregulation should be accurately selected and monitored. Further research is necessary to better assess the true prevalence and preventive measures of skin reactions to COVID-19 vaccination.
ABSTRACT
In March 2019, the World Health Organization (WHO) recognized the COVID-19 pandemic as a global issue. To reduce the spread of this disease, health safety pathways were implemented worldwide. These extraordinary measures changed people's lifestyles, e.g., by being forced to isolate, and in many cases, to work remotely from home. Low back pain (LBP), the most common cause of disability worldwide, is often a symptom of COVID-19. Moreover, it is often associated with different lifestyle features (type of job, physical activity, body weight). Therefore, the purpose of this systematic review and meta-analysis was to estimate the effect of the COVID-19 lockdown on LBP intensity and prevalence compared with LBP rates before the pandemic. A systematic search was performed on Scopus, PubMed, and Cochrane Central. Overall, eight studies with 2365 patients were included in the analysis. We used the Joanna Briggs Institute (JBI) critical appraisal tool to evaluate the risk of bias: six studies (75%) were at moderate risk of bias and two studies (25%) were at low risk of bias. These studies showed an increase in both the prevalence and intensity of LBP during the COVID-19 lockdown.
Subject(s)
COVID-19 , Low Back Pain , COVID-19/epidemiology , Communicable Disease Control , Humans , Low Back Pain/epidemiology , Pandemics , PrevalenceABSTRACT
Background: Patients affected by pre-existing chronic spontaneous/Inducible urticaria (CSU/CIU) still feel unsafe due to the potential risk of an Adverse Event Following Immunization (AEFI) and Cutaneous Adverse Reactions (CARs) of COVID-19 vaccines. The appropriate management in this field remains debated and evidence is still lacking. Methods: We considered 160 CSU/CIU patients in Omalizumab/antihistamine therapy who received two doses of Comirnaty/Moderna mRNA vaccines;20 of them also received a booster dose. Urticaria Activity Score-7 (UAS7) was used to assess the severity of the disease. Demographics, medical history, AEFI and CARs outcome after vaccination were collected by administering a web-based questionnaire completed by phone interview. Results: In total, 147 patients did not show urticaria relapse (91.88%). Worsening cutaneous symptoms were experienced by 13 of our patients (8.12%). Exacerbation had a mean duration of 2 days and 11 h and mostly occurred after the first dose (69.23%). Systemic mild side effects were experienced by 9 patients (5.62%). No severe reactions were observed. Conclusions: Omalizumab can potentially prevent CARs and AEFI;however, major problems were registered during the 2-month stop period scheduled in the treatment. We suggest patients should not undergo vaccination during this period. CSU/CIU exacerbations appear to be transient and can be managed by antihistamines.
ABSTRACT
The current coronavirus disease 2019 (COVID-19) pandemic has revolutionized global healthcare in an unprecedented way and with unimaginable repercussions. Resource reallocation, socioeconomic confinement and reorganization of production activities are current challenges being faced both at the national and international levels, in a frame of uncertainty and fear. Hospitals have been restructured to provide the best care to COVID-19 patients while adopting preventive strategies not to spread the infection among healthcare providers and patients affected by other diseases. As a consequence, the concept of urgency and indications for elective treatments have been profoundly reshaped. In addition, several providers have been recruited in COVID-19 departments despite their original occupation, resulting in a profound rearrangement of both inpatient and outpatient care. Orthopaedic daily practice has been significantly affected by the pandemic. Surgical indications have been reformulated, with elective cases being promptly postponed and urgent interventions requiring exceptional attention, especially in suspected or COVID-19+ patients. This has made a strong impact on inpatient management, with the need of a dedicated staff, patient isolation and restrictive visiting hour policies. On the other hand, outpatient visits have been limited to reduce contacts between patients and the hospital personnel, with considerable consequences on post-operative quality of care and the human side of medical practice.In this review, we aim to analyze the effect of the COVID-19 pandemic on the orthopaedic practice. Particular attention will be dedicated to opportune surgical indication, perioperative care and safe management of both inpatients and outpatients, also considering repercussions of the pandemic on resident education and ethical implications.